A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1-3 prior lines of therapy
Protocol No
79635322MMY3002/TRIlogy-5
Trial information
Medical condition
MM
Trial phase
Phase 3
Sponsor
J&J
Start date
17/07/2026
End date
End of 2030
Main objective
To compare the efficacy and safety of JNJ-79635322 versus teclistamab in participants with relapsed/refractory multiple myeloma after 1–3 prior lines of therapy.
Locations and Contact points
Greece
Site city
Organisation name
Department name
Name
Email
Telephone number
Ioannina
University General Hospital of Ioannina
Department of Hematology, Clinical Studies Office
Eleftheria Hatzimichael
Olga Siarabi
2651099650
Cookies and your privacy
We use essential cookies to make this site work. With your consent, we also use Google Analytics cookies to measure visits and improve the site. You can change your choice at any time.
